![]() |
![]() |
FDA Home Page |
Search FDA Site | A-Z Index | Contact FDA
![]()
Back to Budget Documentation Page
Back to FY 2006 Budget Summary
Table of Contents
|
FY 2004 Actual |
FY 2005 Enacted 1/ |
FY 2006 Estimate |
Increase or Decrease |
|
|
Program Level |
$158,010,00 |
$165,344,000 |
$171,394,000 |
+$6,050,000 |
|
Budget Authority |
$150,397,000 |
$149,237,000 |
$153,337,000 |
+ $4,100,000 |
| GSA Rent and Other Rent Related Activities: | ||||
| Foods Program | $23,168,000 |
$23,187,000 |
$23,615,000 |
+ $428,000 |
| Human Drugs Program | $18,544,000 |
$20,059,000 |
$20,518,000 |
+ $459,000 |
| Biologics Program | $7,272,000 |
$5,979,000 |
$6,039,000 |
+ $60,000 |
| Animal Drugs & Feeds Program | $12,043,000 |
$12,259,000 |
$12,477,000 |
+ $218,000 |
| Devices and Rad. Health Program | $16,315,000 |
$17,702,000 |
$18,012,000 |
+ $310,000 |
| National Center for Toxicological Research | $217,000 |
$229,000 |
$229,000 |
$0 |
| Office of Regulatory Affairs Program | $64,416,000 |
$62,526,000 |
$65,001,000 |
+ $2,475,000 |
| Other Activities Program | $8,422,000 |
$7,296,000 |
$7,446,000 |
+ $150,000 |
|
User Fees |
$7,613,000 |
$16,107,000 |
$18,057,000 |
$1,950,000 |
| GSA Rent and Other Rent Related Activities: | ||||
| PDUFA | $6,146,000 |
$12,407,000 |
$12,700,000 |
+ $293,000 |
| MDUFMA | $1,367,000 |
$3,329,000 |
$3,986,000 |
+ $657,000 |
| ADUFA | $100,000 |
$371,000 |
$1,371,000 |
+ $1,000,000 |
Includes structure changes to FDA's budget, which displays GSA and Other Rent and Rent Related Activities in the Program line, and the Office of Regulatory Affairs as its own program. ORA estimates are for information purposes only and are not included in the Center program level total.
1Contains budget authority rescission of 0.8 percent.
| Historical Funding and FTE Levels | ||||
|---|---|---|---|---|
|
Fiscal Year |
Program Level |
Budget Authority |
User Fees |
Program Level FTE |
|
2002 Actual 1/ |
$99,916,000 |
$98,876,000 |
$1,040,000 |
0 |
|
2003 Actual |
$150,511,000 |
$141,292,000 |
$9,219,000 |
0 |
|
2004 Actual |
$158,010,000 |
$150,397,000 |
$7,613,000 |
0 |
|
2005 Enacted |
$165,344,000 |
$149,237,000 |
$16,107,000 |
0 |
|
2006 Estimate |
$171,394,000 |
$153,337,000 |
$18,057,000 |
0 |
Does not contain GSA Rent or Other Rent and Rent Related Activities.
1/Includes FDA's FY 2002 Appropriation and the Counterterrorism Supplemental.
The Agency is requesting $171,394,000 in program level resources for both government-owned and GSA-leased property, as needed for staff to accomplish FDA's mission. Rent is part of the Salaries and Expenses Appropriation and includes Rental Payments to GSA and Other Rent and Rent-Related Activities. GSA Rental Payments includes charges for all of GSA space, while the Other Rent and Rent-Related account includes rent and rent-related charges that are not part of the GSA account.
This request, for Budget Authority and User Fees, supports various activities that contribute to the accomplishment of program outputs and performance goals, and presents FDA's justification of base resources by strategic goals.
To provide increased flexibility and accountability, eliminate the need for the many reprogramming requests to the Congress, place the accountability for rental costs within the operating program, and would better reflect the total cost of each program. This budget changes the way the GSA Rent and Other Rent-Related Activities budget lines are displayed by incorporating these resources into program level requests.
This budget also establishes a single budget line item for the Office of Regulatory Affairs (ORA), to help it provide services more effectively, especially by providing much needed flexibility to respond shifting program priorities. This additional flexibility is essential to allow FDA to respond to emerging situations without being hindered in performing its mission critical activities. These activitieshave been removed from each program line and theField estimates will be provided under the ORA to reflect the planned spending for each program area.
To help meet the rising costs of GSA rent, a total increase of $4,100,000 is requested to help cover inflation on FDA's current GSA leased facilities.
PDUFA authorized the FDA to collect fees from the pharmaceutical industry to augment appropriations spent on drug review. These fees expand the resources available for the process of reviewing human drug applications including reviewers, information management, space costs, acquisition of fixtures, furniture, equipment and other necessary materials so that safe and effective drug products reach the American public more quickly. The BT Act reauthorized the collection of user fees to enhance the review process of new human drugs and biological products and established fees for applications, establishments, and approved products. These amendments are effective for five years and direct FDA to strengthen and improve the review and monitoring of drug safety; consider greater interaction with sponsors during the review of drugs and biologics intended to treat serious diseases and life-threatening diseases; and develop principles for improving first-cycle reviews. The increases will contribute to meeting these mandated directives.
The FY 2006 requestfor the Devices and Radiological Health program meetsthe required trigger of $220,961,000 in the Devices and Radiological Health Program, enabling FDA to collect the MDUFMA user fees that supplement the appropriated portion of the medical device review program. The Agency will be able to continue its efforts to improve the quality and timeliness of the medical review process and promote the delivery of new medical technologies to the American public. The MDUFMA User Fees it collects will allow FDA to continue to:
ADUFA enacted in November 2003, contained a required appropriations action enabling FDA's implementation of ADUFA. ADUFA helps the FDA, through a strengthened animal drug pre-market review program, to provide greater public health protection by ensuring that animal drug products that are approved to be safe and effective are readily available for both companion animals and animals intended for food consumption. Additional resources provided by ADUFA will also help FDA scientists keep pace with the rapid advances in science and medicine that drive the quality of health care for our animals. ADUFA, which requires new animal drug applicants, sponsors, and manufacturers to incur a fee to expedite their respective applications, will help provide a cost-efficient, high quality animal drug review process that is predictable and performance driven.
Through improving FDA's business practices, the Agency will ensure a world-class professional work force, effective and efficient operations and adequate resources to accomplish the mission. FDA will continue to:
![]()